TARGET THERAPIES AND BIOMARKERS IN BREAST CANCER: A LITERATURE REVIEW
DOI:
https://doi.org/10.47820/recima21.v5i5.5293Keywords:
Targeted therapies. Biomarkers. Breast cancer. Breast cancer treatment. Evaluation of biomarkers.Abstract
Breast cancer is one of the leading causes of morbidity and mortality among women worldwide, representing a significant public health challenge. One of the main advances in breast cancer therapy has been the development of target therapies, which aim to target specific components of tumor cells responsible for cancer growth and spread. Objective: This article aims to carry out a literature review of the latest advances in target therapies and biomarkers in breast cancer. Methods: A systematic search of the scientific literature was carried out using databases such as PubMed, Web of Science, Scopus and Google Scholar. Original studies and reviews published between 2009 and 2024, in English, Portuguese or Spanish, related to target therapies, biomarkers and breast cancer were included. Results and Discussion: The analysis of the studies revealed significant advances in target therapies, such as trastuzumab and CDK4/6 inhibitors, as well as the importance of biomarkers, such as Ki-67 and hormone receptors, in predicting response to treatment. The positive economic impact of target therapies and biomarkers in reducing long-term healthcare costs was also highlighted. Conclusion: Targeted therapies and biomarkers represent fundamental advances in the treatment of breast cancer, offering a more personalized, effective and economical approach. The contribution of these strategies to clinical practice and decision-making underscores the continued importance of research and application of scientific advances in oncology.
Downloads
References
AKRAM, Muhammad et al. Awareness and current knowledge of breast cancer. Biological research, v. 50, p. 1-23, 2017. DOI: https://doi.org/10.1186/s40659-017-0140-9
ANDRE, Fabrice et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. Journal of Clinical Oncology, v. 40, n. 16, p. 1816-1837, 2022. DOI: https://doi.org/10.1200/JCO.22.00069
BARZAMAN, Khadijeh et al. Breast cancer: Biology, biomarkers, and treatments. International immunopharmacology, v. 84, p. 106535, 2020. DOI: https://doi.org/10.1016/j.intimp.2020.106535
BRAVO, Barbara Silva et al. Câncer de mama: uma revisão de literatura. Brazilian Journal of Health Review, v. 4, n. 3, p. 14254-14264, 2021. DOI: https://doi.org/10.34119/bjhrv4n3-357
CARDOSO, Fatima et al. 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3). The Breast, v. 31, p. 244-259, 2017. DOI: https://doi.org/10.1016/j.breast.2016.10.001
COSTA, Laise Soares et al. Fatores de risco relacionados ao câncer de mama e a importância da detecção precoce para a saúde da mulher. Revista Eletrônica Acervo Científico, v. 31, p. e8174-e8174, 2021. DOI: https://doi.org/10.25248/reac.e8174.2021
GNANT, Michael; HARBECK, Nadia; THOMSSEN, Christoph. St. Gallen/Vienna 2017: a brief summary of the consensus discussion about escalation and de-escalation of primary breast cancer treatment. Breast Care, v. 12, n. 2, p. 101-106, 2017. DOI: https://doi.org/10.1159/000475698
INCA - INSTITUTO NACIONAL DE CÂNCER. Estimativa 2020: incidência de câncer no Brasil. Rio de Janeiro: INCA, 2019.
KORDE, Larissa A. et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. Journal of Clinical Oncology, v. 39, n. 13, p. 1485, 2021. DOI: https://doi.org/10.1200/JCO.20.03399
LEE, Kyuwan et al. The impact of obesity on breast cancer diagnosis and treatment. Current oncology reports, v. 21, p. 1-6, 2019. DOI: https://doi.org/10.1007/s11912-019-0787-1
LITTON, Jennifer K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine, v. 379, n. 8, p. 753-763, 2018. DOI: https://doi.org/10.1056/NEJMoa1802905
LIU, Mei et al. Cell‐specific biomarkers and targeted biopharmaceuticals for breast cancer treatment. Cell proliferation, v. 49, n. 4, p. 409-420, 2016. DOI: https://doi.org/10.1111/cpr.12266
MAUGHAN, Karen L.; LUTTERBIE, Mark A.; HAM, Peter S. Treatment of breast cancer. American family physician, v. 81, n. 11, p. 1339-1346, 2010.
MUTEBI, Miriam et al. Breast cancer treatment: A phased approach to implementation. Cancer, v. 126, p. 2365-2378, 2020. DOI: https://doi.org/10.1002/cncr.32910
NEVES REBELLO ALVES, Lyvia et al. Biomarkers in breast cancer: an old story with a new end. Genes, v. 14, n. 7, p. 1364, 2023. DOI: https://doi.org/10.3390/genes14071364
ODLE, Teresa G. Precision medicine in breast cancer. Radiologic technology, v. 88, n. 4, p. 401M-421M, 2017.
ONKAR, Sayali S. et al. The great immune escape: understanding the divergent immune response in breast cancer subtypes. Cancer discovery, v. 13, n. 1, p. 23-40, 2023. DOI: https://doi.org/10.1158/2159-8290.CD-22-0475
PRAT, Aleix et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. The Breast, v. 24, p. S26-S35, 2015. DOI: https://doi.org/10.1016/j.breast.2015.07.008
ROSSI, Lorenzo; MAZZARA, Calogero; PAGANI, Olivia. Diagnosis and treatment of breast cancer in young women. Current treatment options in oncology, v. 20, n. 12, p. 86, 2019. DOI: https://doi.org/10.1007/s11864-019-0685-7
ROULOT, Aurélie et al. Hétérogénéité tumorale des cancers du sein. Annales de Biologie Clinique, p. 653-660, 2016. DOI: https://doi.org/10.1684/abc.2016.1192
SANTOS, Tainá Bastos dos et al. Prevalência e fatores associados ao diagnóstico de câncer de mama em estágio avançado. Ciência & Saúde Coletiva, v. 27, p. 471-482, 2022. DOI: https://doi.org/10.1590/1413-81232022272.36462020
SARHANGI, Negar et al. Breast cancer in the era of precision medicine. Molecular Biology Reports, v. 49, n. 10, p. 10023-10037, 2022. DOI: https://doi.org/10.1007/s11033-022-07571-2
SCUDELER, Mariana M. et al. Breast cancer pharmacogenetics: a systematic review. Pharmacogenomics, v. 24, n. 2, p. 107-122, 2023. DOI: https://doi.org/10.2217/pgs-2022-0144
SHAHBANDI, Ashkan; NGUYEN, Hoang D.; JACKSON, James G. TP53 mutations and outcomes in breast cancer: reading beyond the headlines. Trends in cancer, v. 6, n. 2, p. 98-110, 2020. DOI: https://doi.org/10.1016/j.trecan.2020.01.007
SHIEN, Tadahiko; IWATA, Hiroji. Adjuvant and neoadjuvant therapy for breast cancer. Japanese journal of clinical oncology, v. 50, n. 3, p. 225-229, 2020. DOI: https://doi.org/10.1093/jjco/hyz213
SINGH, Kavita et al. Immunotherapy for Breast Cancer Treatment: Current Evidence and Therapeutic Options. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders), v. 22, n. 2, p. 212-224, 2022. DOI: https://doi.org/10.2174/1871530321666210426125904
SLAMON, Dennis J. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3. Journal of Clinical Oncology, v. 36, n. 24, p. 2465-2472, 2018. DOI: https://doi.org/10.1200/JCO.2018.78.9909
SPARANO, Joseph A. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. New England Journal of Medicine, v. 379, n. 2, p. 111-121, 2018.
SWAIN, Sandra M. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. New England journal of medicine, v. 372, n. 8, p. 724-734, 2015. DOI: https://doi.org/10.1056/NEJMoa1413513
TRAPANI, Dario et al. Global challenges and policy solutions in breast cancer control. Cancer treatment reviews, v. 104, p. 102339, 2022. DOI: https://doi.org/10.1016/j.ctrv.2022.102339
VALLE-SOLÍS, Aura Erazo et al. Supervivencia en cáncer de mama por subtipo mediante inmunohistoquímica: Un estudio retrospectivo. Gaceta médica de México, v. 155, p. 50-55, 2019. DOI: https://doi.org/10.24875/GMM.19005133
VAN DEN ENDE, Nadine S. et al. Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review. International Journal of Molecular Sciences, v. 24, n. 3, p. 2969, 2023. DOI: https://doi.org/10.3390/ijms24032969
Downloads
Published
How to Cite
License
Copyright (c) 2024 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
Clique para ver detalhes 
